Category: Featured

New Race non-executive director Dr John Cullity has used his first interview to highlight the company’s growth potential.

Race Oncology has announced it has executed a global distribution agreement with UK-based, Durbin PLC. Durbin distributes pharmaceutical and healthcare products to 180 countries worldwide. They have global expertise in managed access programs, such as named patient programs (NPP). Under…

Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US, and he has consulted to…

In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million. As a former Director of Viralytics from 2008 – 2014, current Race Oncology Managing Director…

Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address at the BIO CEO Conference in New York City.

A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs…

Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief Executive Peter Molloy will present on Monday 8 January,…

Betadine is the largest selling sore throat treatment in Australia. But it almost never made it to the shelves of our pharmacies and supermarkets. The active ingredient was developed by an American pharmaceutical company that wanted to keep Betadine purely…

Race Oncology Limited (ASX: RAC) announced today that it has executed a Letter of Intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a joint venture between the two companies. The joint venture, to be called Race Immunotherapeutics, will…